DAFTAR PUSTAKA

Abbas, AK. 2007. *Cellular and molecular Immunology, 6th Edition*. Elsevier, Philadelphia.

Akishita, M. 2004. Atherosclerosis and Hyperlipidemia. *JMAJ*. 47 (4): 175-178.

Black M, Ketelhuth DF, Agewall S. 2010. Matrix metalloproteinases in atherothrombosis. *Prog Cardiovasc Dis*. 52: 410-428.

Boamponsen AG, Bomponsen L K. 2011. The role of inflammation in atherorosclerosis. *Advances in Applied Science Research*. 2 (4): 194-207.

Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, *et al*. 2001. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *New Engl J Med* . 345 (22): 23-28.

Brusic V, Bajic VB, and Petrovsky N. 2004. Computational methods for prediction of T-cell epitopes a framework for modelling, testing, and applications. *Methods*, 34 (4): 436–443.

Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston A, Delignat S, and Mandet C. 2007. Phosphorylcholine-targeting immunization reduces atherosclerosis. *Journal of the American College of Cardiology*. 50 (6): 540-546.

Chen K, Hsieh I, Hsi E, Wang Y, Dai C, Chou W, *et al*. 2011. Negative feedback regulation between microRNA let-7gandtheox LDL receptor LOX-1. *Journal of Cell Science*. 124: 4115-4124.

Chen XP, Zhang TT, and Du GH. 2007. Lectin-like oxidized low-density lipoprotein receptor-1, a new promising target for the therapy of atherosclerosis?. *Cardiovascular Drug Reviews*. 25 (2): 146–161.

Chrowter MA. 2005. Pathogenesis of Atherosclerosis. *Haematology*. 1: 437-447.

Claverie M J and Notredame C. 2003. *Bioinformatics for Dummies*. Research Scientist, UC Santa Cruz.

Curtiss LK. 2009. Reversing atherosclerosis. *New Eng. J. of Med.* 360: 11.

Dahlan S. 2011. *Statistika untuk Kedokteran dan Kesehatan.* Penerbit Salemba Medika, Jakarta.

Departemen Kesehatan Direktorat Jenderal Pengawasan Obat dan Makanan. 1995. *Farmakope Indonesia Edisi IV*. Departemen Kesehatan, Jakarta.

Departemen Kesehatan Republik Indonesia. 2010. Risiko utama penyakit tidak menular disebabkan rokok. http://depkes.go.id/index.php/berita/press-release/1386-risiko-utamapenyakittidak-menulasr-disebabkan-rokok.html.

Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. 2006. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. *Diabetes.* 55: 774 –779.

Dominguez JH, Mehta JL, Li D, Wu P, Kelly KJ,Packer CS, Temm C, Goss E, Cheng L, Zhang S, Patterson CE, Hawes JW, Peterson R. 2008. Anti-LOX-1 thera[y in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestation. *Am J Physiol Renal Physiol,* 294: F110-F119.

Doran AC, Meller N, McNamara CA. 2008. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 28: 812e9

Ebraheim AM, Reda AM, Farghaly M, El-hoseiny RM, and Shafee SE. 2010. Presymptomatic atherosclerosis: association with cardiovascular risk factors and role of inflammatory mediators. *Egypt J Neurol Psychiat Neurosurg.* 50 (2): 149-156.

Elio G, Enrico V, Ivano B, Barbara P, Paolo DP, Rimlardo R*, et al.* 2013. LOX-1 and its implications on cardiovascular diseases a possible new perspective target on atherosclerosis. *J Clin Exp Cardiolog.* 4: 1-5.

El-Shatanovi, Ashoush IS, Ahmed EK, Ali SA. 2012. Antiatherogenic properties of vegetablenjuice rich in antioxidant in cholesterol-fed-rats. *Annals of Agriculture Science*, 57 (2): 167-173.

Ewing SL, Lagrost L, Neel D.. 2012. Lipid Raft: A Signalling Platform Linking Lipoprotein Metabolism To Atherogenesis. *Atherosclerosis*, 211: 303-310.

Federer WT. 1955. *Experimental Design: Theory and Application.* Oxford & IBH Publishing Company, London.

Fredrikson GN, Bjorkbacka H, Soderberg I, Ljungcrantz I, and Nilsson J. 2010. Treatment with apo B peptida vamlines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptida-specific antibodies. *Journal of Internal Medicine.* 264: 563-570.

Frostegard J. 2013. Immunity, atherosclerosis and cardiovascular disease. *BMC medicine.* 11: 117-130.

Groves MJ. 2006. *Pharmaceutical Biotechnology Second Edition.* Taylor & Francis Group LLC, London.

Gaal LFV, Mertens IL, and Block CED. 2006. Mechanisms linking obesity with cardiovascular disease. *Nature.* 444: 875-880.

Guyton AC and Hall JE. 2008. *Buku Ajar Ilmu Fisiologi Kedokteran Edisi 11*. Jakarta: Penerbit Buku Kedokteran EGC.

Handayani D, Chen J, Meyer BJ, and Huang XF. 2011. Dietary shiitake mushroom (*lentinus edodes*) prevents fat deposition and lowers triglyceride in rats fed a high-fat diet. *Journal of Obesity*. 1-8.

Handayani D, Meyer BJ, Chen J, Tang P, Kwok PCL, Chan HK, et al. 2012. The comparison of the effect of oat and shiitake mushroom powder to prevent body weight gain in rats fed high fat diet. *Food and Nutrition Sciences*. 1009-1019.

Hansson GK. 2005. Inflammation, atherosclerosis, and corornary artery disease. *New England Journal of Medicine*. 352: 1685-1695.

Harrison D, Griendling KK, Landmesser U, Hornig B, and Dexler H. 2003. Role of oxidative stress in atherosclerosis. *Am. J. Cardiol*. 91: 7A-11A.

Hermonat PL, Zhu H, Cao M, Mehta JL. 2011. LOX-1 transcription. *Cardiovasc Drugs Ther,* 25: 393-400.

Herpandi. 2005. *Aktivitas hipokolesterolemik tepung rumput laut pada tikus hiperkolesterolemia.* Tesis, Tidak diterbitkan, Fakultas Perikanan dan Ilmu Kelautan, Bogor.

Hong D, Bai YP, Gao HC, Wang X, Li LF, Zhang GG *et al.* 2014. O x-LDL induces endothelial cell apoptosis via the LOX-1-dependent endoplasmic reticulum stress pathway. *Atherosclerosis*, 225: 310-317.

Hu C, Dandapat A, SunL, Khan JA, Liu Y, Hermonat PL, *et al.* 2008. Regulation of TGFβ1-mediated collagen formation by LOX-1: Studies based on forced overexpression of TGFβ1 in wild type and LOX-1. *J. Biol. Chem,* 283: 10226-10231.

International Atherosclerosis Society. 2011a. An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia, Executive Summary.

International Atherosclerosis Society. 2011b. Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease., Executive Summary.

Iwamoto S, Nishimichi N, Tateishi Y, Sato Y, Horiuchi H, Furusawa S, Sawamura T, Matsuda H. 2009. Generation and characterization of chicken monoclonal antibodies against human LOX-1/ Report Landes Bioscience, *mAbs*,1:4, 357-363.

Jan M, Meng S, Chen N C, Mai J, Wang H, and Yang XF. 2010. Inflammatory and autoimmune reactions in atherosclerosis and vamline design informatics. *Journal of biomedicine & biotechnology*. 1-16.

Khallou-Laschet, J., Tupin, E., Caligiuri, G. 2005. Atheroprotective Effect of Adjuvants in Apolipoprotein E Knockout Mice. *Atherosclerosis.*

Kitahara M, Kanaki M, Ishii I and Saito Y. 2010. Atherosclerosis induced by chronic inhibition of the synthesis nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin. Br J Pharmacol. 159 (7): 1418–1428.

Kliegman RM, Behrman RE, Jenson HB, Stanton BF. 2007. *Nelson Textbook of Pediatric* (18th Edition). Saunders, New York.

Kuramochia MK, Xie Q, Kajiwara S, Komba S, Minowa T, Machida S. 2013. Lectin-like oxidized LDL receptor-1 is palmitoylated and internalizes ligands via caveolae/raft-dependent endocytosis. *Biochemical and Biophysical Research Communications*, 434: 594-599.

Kusumawati D. 2004. *Bersahabat dengan Hewan Coba*. Gajah Mada University Press, Yogyakarta.

Lau DCW, Dhillon B, Yan H, Szmitko PE, and Verma S. 2005. Adipokines: molecular links between obesity and atherosclerosis. *Am. J. Physiol. Heart Circ. Physiol.* 288: H2031–H2041.

Libby P, Ridker PM, and Hansson GK. 2011. Progress and challenges in translating the biology of atherosclerosis. *Nature.* 473: 317-325.

Li D and Mehta JL. 2009. Intracellular signaling of LOX-1 in endothelial cell apoptosis. *Journal of The American Heart Association.* 104: 566-568

Littleton LC and Gruenke JA. 2013. A comparison of the effect of three adjuvants on the antibody response to ovalbumin in mice. *BIOS*, 84(3):142-147

Lu L, Liu H, Peng J, Gan L, Shen L, Zhang Q, *et al.* 2010. Regulations of the key mediators in inflammation and atherosclerosis by Aspirin in human macrophages. *Lipids in Health and Disease.* 9: 16-23.

Mallat Z, Ait-Oufella H, 2007. Regulatory T-cell immunity in atherosclerosis. *Trends Cardiovasc Med..* 17: 113–118.

Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J, *et al.* 2007. Modulation of ADP-Induced Platelet Activation by Aspirin and Pravastatin: Role of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1, Nitric Oxide, Oxidative Stress, and Inside-Out Integrin Signaling. *The Journal of Pharmacology and Experimental Therapeutic*, 322 (3): 1324-1332.

Matarazzo S, Quitadamo MC, Mango R, Ciccone S, Novelli D, and Biocca S. 2012. Cholesterol-Lowering Drugs Inhibit Lectin-Like Oxidized LowDensity Lipoprotein-1 Receptor Function by Membrane Raft Disruption. *Molecular pharmacology*, 82 (2): 246-254.

Mathers CD and Loncar D. 2006. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med*. 3 (11): 442.

Mazzone T, Chait A, Plutzky J. 2008. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. *Lancet*. 371: 1800–1809.

Mcentyre J and Ostell J. 2005. *The NCBI Handbook*. National Library of Medicine, Bethesda (US).

McGill H.C., McMahan, C.A., Herderick, E., Malcom, G.T., Tracy, R.E., Strong, P.J. 2000. Origin of atherosclerosis in childhood and adolescence. *American Journal of Clinical Nutrition*, Vol. 72 : 1307-1315.

McLaren JE, Michael DR, Ashlin TG, Dipak P. 2011. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. *Prog Lipid Res*. 50: 331-347.

Murugappa S and Kunapuli SP. 2006. The role of ADP receptors in platelet function. Front Biosci. 1(11): 1977-1986

Murwani S, Ali M, Muliartha K. 2008. Diet aterogenik pada tikus putih (*Rattus norvegicus galur wistar)* sebagai model hewan aterosklerosis. *Jurnal Kedokteran Brawijaya*: 6-10.

Nilsson J, Hansson GK. 2008. Autoimmunity in atherosclerosis: a protective response losing control*? J Intern Med*. 263: 464–478.

Nilsson J, Fredrikson GN, Bjorkbacka H, Chyu KY, and Shah PK. 2009. Vamlines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. *Journal of Internal medicine*. 1365-2796.

Oufella HA, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, *et al.* 2010. B cell depletion reduces the development of atherosclerosis in mice. *The Journal of Experimental Medicine*. 207(8): 1579-1587.

Pang J, Xu Q, Xu X, Yin H, Xu R, Guo S, *et al.* 2010. Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. *Peptida*, 31: 630–638.

Panigoro R, Greville WD, Kennedy A, Trejaut J, Dunckley H. 1999. New HLA class II alleles in the Indonesian population. *Tissue Antigen*, 54 (5): 521-523.

Pauwels R, Bazin H, Platteau B and Straeten MVD. 1979. The influence of antigen dose on IgE production in different rat galur. *Immunology*. 36: 151-157.

Pellizon MA. 2009. *Diet- induced atherosclerosis/hypercholesterolemia in rodent models*. Research Diets, Inc.

Prasad DS, Kabir Z, Dash AK, Das BC. 2009. Smoking and cardiovascular health: A review of the epidemiology, pathogenesis, prevention and control of tobamlo. *Indian Journal of Medical Sciences*. 63 (11): 520-533.

Pratama MZ. 2011. *Pengaruh pemberian vaksin bakteri Salmonella thypimurium terhadap progresivitas aterosklerosis dan obesitas pada tikus wistar jantan yang diberi diet tinggi lemak*. Tugas Akhir, Tidak diterbitkan, Fakultas Kedokteran Universitas Brawijaya, Malang.

Pirillo A, Norata GD, Catapano AL. 2013. LOX-1, OxLDL, and atherosclerosis: mediators of inflammation. *Hindawi Publishing Corporation*. 152786.

Reeves, PG, Nielsen FH, and Fahey GC. 1993. *AIN-93 Purified Diets for Laboratory Rodents : Final Report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of AIN-76A Rodents Diet*. United States Departement of Agriculture, University of Illinois, Urbana.

Riset Kesehatan Dasar (RISKESDAS). 2007. Jakarta: Badan Penelitian dan Pengembangan Kesehatan. Departemen Kesehatan Republik Indonesia.

Saha S and Raghava GPS. 2006. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. *Proteins: Structure, Function and Genetics*. 65 (1): 40–48.

Samson S, Mundkur L and Kakkar VV. 2012. immune response to lipoproteins in atherosclerosis. *Hindawi Publishing Corporation Cholesterol*. 1-12.

Sanches PL, Mello MT, Elias N, Fonseca FAH, Piano A, Carnier J. 2011. Improvement in HOMAIR is an independent predictor of reduced carotid intima-media thickness in obese adolescents participating in an interdisciplinary weight-loss program. *Hypertension Res.*. 34: 232–238.

Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, *et al.* 1997. An endothelial receptor for oxidized low-density lipoprotein. *Nature*. 386: 73-77.

Shirai K, Ishikawa Y, Nishide T, Sasaki N, Murano S, Sato A, *et al.* 1984. Effect of Niceritol on Lipid Metabolism of Aorta in Atherosclerotic Mice. *Tohoku J. Exp. Med*, 143: 231-238.

Stary HC, Chandler BA, Dinsmore RE, Fuster V, Glagov S, Insull W, *et al.* 1995. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. *Circulation*. 92 (5): 1355-1374.

Sun Y and Chen X. 2010. Ox-LDL-induced LOX-1 expression in vascular smooth muscle cells: role of reactive oxygen species. Fundamental & Clinical Pharmacology, 25: 572–579.

Tate S. 2007. OxLDL receptor, LOX-1, on the endothelial cell – the receptor structure and functions of LOX-1 in atherogenesis. *J.Biol.Macromol.* 7 (2): 12-20.

Tedgui A, Mallat Z. 2006. Cytokines in atherosclerosis: pathogenic and regulatory pathways. *Physiol Rev.* 86: 515–81.

Thompson PD, Buchner D, Pina IL, Balady G, William MA, Marcus BA, *et al.* 2003. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. *Circulation Research.* 107: 3109-3116.

Vaughan CJ, Gotto AM, Basson CT. 2000. The evolving role of statins in the management of atherosclerosis. *Journal of the American College of Cardiology.* 35 (1): 1-19.

Wang T, Palumli D, Law K, Yanagawa B, Yam J, Butany J. 2012. Atherosclerosis: pathogenesis and pathology. *Diagnostic Histopathology.* 18 (11): 461-467.

Waghmare S, Gomase V, Chavan R, and Kale KV. 2012. Prediction of Major Histocompatibility Complex Binding Peptidas and Epitopes from Fatty-Acid-Binding Protein of the Human Blood Fluke Schistosoma Japonicum. *Metabolomics.* 2 (4): 1-6.

Weinreich O, Vanpinxteren LA, Okkels LM, Rasmussen BP, Endersen A. 2001. Protection of Mice with a Tuberculosis Subunit Vamline Based on a Fusion Protein of Antigen 85B and ESAT-6. Infection and Immunity: 1773-1778.

Wikarek BM, Kocelak P, Smertka M, Glinianowicz MO, Chudek J. 2012. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis - guidelines *vs.* reality. *Pharmacological Reports.* 64: 377-385.

Wigren M, Bengtsson D, Dunér P, Olofsson K, Björkbacka H, Bengtsson E, *et al.* 2009. Atheroprotective Effects of Alum Are Associated With Capture of Oxidized LDL Antigens. *Circulation Research..* 104: 62-70.

World Health Organization. 2011a. *Global status report on noncommunicable disaeses 2010.* Geneva.

World Health Organization. 2011b. *Global atlas on cardiovascular disease prevention and control.* Geneva.